BC Week In Review | Feb 16, 2018
Clinical News

Boehringer discontinues PDE-9A inhibitor for AD

Boehringer Ingelheim GmbH (Ingelheim, Germany) discontinued development of BI 409306 to treat Alzheimer's disease after the candidate missed the efficacy endpoints in two Phase II trials in the indication. BI 409306 is a phosphodiesterase-9A (PDE-9A)...
BC Extra | Feb 9, 2018
Clinical News

Boehringer discontinues PDE-9A inhibitor for AD

Boehringer Ingelheim GmbH (Ingelheim, Germany) discontinued development of BI 409306 to treat Alzheimer's disease after the candidate missed the efficacy endpoints in two Phase II trials in the indication. BI 409306 is a phosphodiesterase-9A (PDE-9A)...
Items per page:
1 - 2 of 2